Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT01204112
• Date of registration: 15/09/2010
• Primary sponsor: Pfizer
• Public title: Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers
• Scientific title: A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers
• Date of first enrolment: September 2010
• Target sample size: 12
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01204112
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Countries of recruitment

United States

Contacts

• Name: Pfizer CT.gov Call Center
• Affiliation: Pfizer

Key inclusion & exclusion criteria

Inclusion Criteria:

- Healthy male and/or female subjects (of non-childbearing potential)

Exclusion Criteria:

- Clinically significant disease or condition

- Recent serious infection



Age minimum: 18 Years
Age maximum: 55 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Healthy

Intervention(s)

Drug: Tasocitinib (CP-690,550) plus Rifampin

Primary Outcome(s)

AUCinf of tasocitinib (CP-690,550) [Time Frame: 9 days]

Cmax of tasocitinib (CP-690,550) [Time Frame: 9 days]

Secondary Outcome(s)

AUClast, Tmax, t1/2 of tasocitinib (CP-690,550) [Time Frame: 9 days]

Safety: clinical laboratory abnormalities, AE reporting, and vital signs (blood pressure/pulse rate). [Time Frame: 9 days]

Secondary ID(s)

A3921056

Source(s) of Monetary Support

Please refer to primary and secondary sponsors